None listed
Conditions
Brief summary
Women with Gestational Diabetes (GDM) are recommended to monitor their blood glucose levels (BGLs) aiming at tight control to improve the risk of adverse outcomes. After initial review, our service undertakes weekly phone or email contact with women for surveillance of glycaemia. This creates a significant treatment burden for the patient and clinician. We are investigating the use of the Net-Health mobile phone application (app) and linked glucose meter, as part of a blood glucose management system in women with GDM. This app: 1) Automatically uploads BGLs in real time to a secure server for review remotely by the treating team; 2) Automatically generates an email alert to the treating team if BGLs are out of target range; 3) Allows messaging via the app for dose titration if required. We plan to undertake a pilot study of 100 women, recruited from our GDM group education session. Data will be collected to assess feasibility, patient satisfaction and resource utilisation. We will also gather data to explore patterns of glycaemia, maternal and neonatal outcomes. We hypothesize this management system will be feasible and will lead to a more efficient and responsive model of care and use of resources.
Interventions
This study of women diagnosed with Gestational Diabetes Mellitis (GDM) will investigate the feasibility, acceptability and patient satisfaction with the use of the Net-Health smartphone application (app).
The app will collect baseline information at time of registration including age, ethnicity, family history of type 2 diabetes, height, pre pregnancy weight, gestational weight gain, gestation, number of previous pregnancies and previous GDM (including type of treatment).
After registration, t
This study of women diagnosed with Gestational Diabetes Mellitis (GDM) will investigate the feasibility, acceptability and patient satisfaction with the use of the Net-Health smartphone application (app). The app will collect baseline information at time of registration including age, ethnicity, family history of type 2 diabetes, height, pre pregnancy weight, gestational weight gain, gestation, number of previous pregnancies and previous GDM (including type of treatment). After registration, the mobile app will be linked via bluetooth to the blood glucose meter and used to transfer fingerprick BGLs automatically to a secure central server for remote monitoring by the treating team. The app contains some instructions about its use and women will have direct contact details for the diabetes educators if there are any questions about its use. It has the capacity to transfer blood pressure (BP) results from linked home BP machines. The Net-Health server will notify the treating team if 3 or more BGLs are out of range within 1 week via an automatically generated email to prompt expedited phone or clinic review. Duration of the intervention will be from time of consent (after diagnosis between 24-30 weeks gestation) to and will cease after delivery. Adherence will be assessed at clinic appointments with the number of BGL's reviewed and at completion of the study with number of BGL's submitted (compared with expected 4 per day from consent to delivery). Text reminders may be sent at routine follow up of BGL's at prespecified time points in care.
Sponsors
Dr Sophie Poulter
Study design
Allocation
Non-randomised trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Healthy volunteers
No
Inclusion criteria
1. Women with confirmed GDM on routine screening between 24-30 weeks gestation. 2. Singleton pregnancy. 3. Own or have the use of a smartphone. 4. Demonstrate willingness and ability to use a linked glucose meter and mobile phone application. 5. Willing and able to give informed consent.
Exclusion criteria
1. High risk pregnancies not suitable for reduced frequency of review including: • Twins or higher gestation • Known risk factors for obstetric complications (other than obesity or GDM) • Any evidence of fetal compromise 2. GDM diagnosed earlier or later than time period for routine screening (24-30 weeks gestation) that may represent a higher risk of pre-existing diabetes or normal late gestation insulin resistance.
Outcome results
None listed